USFDA concludes inspection at Marksans Pharma Goa facility with zero Form 483 observation
Mumbai: Marksans Pharma has announced that the U.S. Food and Drug Administration (USFDA) has concluded an inspection at the 2nd manufacturing facility at Verna, Goa with Zero Form 483 observation.
The Good Manufacturing Practice (cGMP) inspection was held from 3rd November 2025 to 7th November 2025.
The company headquartered at Mumbai, India is engaged in Research, Manufacturing & Marketing of generic pharmaceutical formulation in the global markets. The company's manufacturing facilities located in India, USA and UK are approved by several leading regulatory agencies including USFDA, UKMHRA and Australian TGA. Marksans's product portfolio spreads over major therapeutic segments of CVS, CNS, Anti-diabetic, Pain Management, Gastroenterological and Antiallergies. The company is marketing these products globally.
Read also: Marksans Pharma UK arm gets marketing nod for Exemestane 25mg film-coated tablets
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.